BTF granted US patent for 'Bioballs'
By Renate Krelle
Thursday, 23 September, 2004
Thursday, 23 September, 2004
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.
The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.
The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.
Related News
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
